SUNNYVALE, Ca., Jan. 13, 2014 /PRNewswire/ -- Silk Road Medical, Inc., a developer of advanced devices for the treatment of Carotid Artery disease, announced today the appointment of Sumaira Macdonald, MD, PhD to the position of Chief Medical Officer effective immediately. In this new role, Dr. Macdonald will direct the company's scientific and technical agenda and lead research in ground breaking endovascular interventions for the prevention and treatment of stroke.
Prior to joining Silk Road Medical Inc., Dr. Macdonald was a Vascular Radiologist and Honorary Clinical Senior Lecturer atNewcastle University and the Freeman Hospital, Newcastle upon Tyne, UK. "To have attracted a clinician of Dr. Macdonald's significant caliber is a testament to the promise of our technology in preventing stroke resulting from carotid artery disease" saidErica Rogers, President and Chief Executive Officer. "Her leadership in clinical research and renowned medical skills will significantly contribute to the advancement of our products and company's growth. We are honored to have her on the team."
Dr. Macdonald is well regarded for her career-long efforts to improve endovascular interventions. In addition to being the Co-Editor of the Springer "Carotid Stenting; A Practical Guide", Dr. Macdonald has authored over 70 medical publications on vascular disease, is the recipient of many academic society honors, serves on the editorial boards of a number of scientific journals and is highly sought after as a speaker, having given over 300 international lectures.
Read more: http://www.prnewswire.com/news-releases/silk-road-medical-appoints-world-renowned-physician-as-chief-medical-officer-239899971.html
Via PR Newswire:
Santa Clara, CA, January 13th, 2014 - ProteinSimple today launched Sally Sue and Peggy Sue, the next generation of high throughput Simple Western instruments. These instruments drive the sensitivity of the current high throughput Simple Western systems to performance levels well beyond any traditional Western.
OncoMed Pharmaceuticals Initiates First Phase 1b Clinical Trial of OMP-54F28 (Fzd8-Fc) With Nab-Paclitaxel (Abraxane(R)) and Gemcitabine in Pancreatic Cancer
REDWOOD CITY, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it has started a multi-center Phase 1b clinical trial of its first-in-class Wnt-pathway-targeting decoy receptor OMP-54F28 (Fzd8-Fc) with nab-paclitaxel (Abraxane®) and gemcitabine in pancreatic cancer. This trial is the first of three Phase 1b trials for OMP-54F28 expected to begin patient enrollment in the next few months as part of OncoMed's collaboration with Bayer Pharma AG. This study follows on the recent initiation of OncoMed's Phase 1b program for the Wnt-pathway-targeting antibody vantictumab (OMP-18R5, Anti-Fzd7).
SANTA CLARA, Calif., Jan. 8, 2014 , PRNewswire -- ProteinSimple today introduced Wes, another revolutionary re-invention of the Western blot. Wes is the bold evolution of the popular Simple Western family of instruments, delivering simplicity and performance like no product before it. With just 30 minutes of sample prep, Wes will analyze up to 25 samples in under 3 hours and he will do it all for less than the price of a high-end Western imager. Wes also introduces an innovative suite of consumables that streamline assay workflow and delivers sensitivity that is better than any traditional Western.
Soft Tissue Regeneration, Inc. Announces Financing and Appoints New Members to Board of Directors
Sara Ansari, R.D. Registered Dietitian, Nutrition Consultant, and Prevent Health Coach joins Lisa and talks anout the biggest obstacles to healthy eating that people face during the holiday season, best tips and strategies to staying healthy while at a holiday party, things people can do to mentally prepare for the holidays, emotional and stress eating and more!
SAN DIEGO, Dec. 19, 2013 – ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. Mr. Foletta is a seasoned financial executive with over 30 yearsof corporate experience. He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc. He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb forapproximately $7 billion in August 2012. During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions. As chair of Amylin’s Operating Committee, he had responsibility for business planning, forecasting and assessing performance. He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M. Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president,Chief Financial Officer and Corporate Secretary.
MALVERN, Pa., Dec. 17, 2013 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the closing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of$7.00 per share, before the underwriting discount and offering costs. As a result, aggregate net proceeds to TetraLogic, after the underwriting discount and offering costs, were approximately $43,100,000.
GUEST MENTOR Andréa Mallard, Chief Brand Officer at Omada Health: As an entrepreneur, the problem with negative feedback of any kind is that it’s instantly personal: they might as well have called your newborn ugly.
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
REDWOOD CITY, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) and Celgene Corporation (Nasdaq:CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).